keyword
MENU ▼
Read by QxMD icon Read
search

CoreValve evolut

keyword
https://www.readbyqxmd.com/read/28893830/assessment-of-paravalvular-leakage-after-transcatheter-aortic-valve-implantation-add-clinical-signs-to-echocardiographic-data
#1
Corstiaan A den Uil, Mihai Strachinaru, Ben van der Hoven, J Han J Meeder
A 62-year old male with pulmonary fibrosis and aortic valve stenosis underwent TAVI (Corevalve Evolut XL 34 mm) in the build-up for lung transplantation (LuTx). Following post-dilation for a large annular perimeter, moderate paravalvular aortic regurgitation (AR) was observed. After 6 weeks, he was admitted to the ICU with respiratory failure(A). TTE demonstrated residual mild AR (based on a small excentric paravalvular AR jet, <10% circumferential extent, pressure half-time was not reliably measured) and together with borderline elevated NT-pro-BNP, the consultant cardiologist authorized LuTx listing...
September 11, 2017: Echo Research and Practice
https://www.readbyqxmd.com/read/28889087/self-expanding-transcatheter-aortic-valve-implantation-for-degenerated-small-mitroflow-bioprosthesis-early-and-midterm-outcomes
#2
Marianna Adamo, Claudia Fiorina, Salvatore Curello, Giuliano Chizzola, Elena Pezzotti, Emanuele Gavazzi, Luca Branca, Ermanna Chiari, Filippo Quinzani, Michele Rinaldi, Marco Metra, Federica Ettori
AIMS: The aim of this study was to report clinical outcomes of self-expanding transcatheter aortic valve implantation (TAVI) for failed small Mitroflow (MF) bioprostheses. METHODS AND RESULTS: Between January 2013 and July 2016, 15 symptomatic patients (NYHA Class ≥III) with degenerated small MF (≤23 mm) underwent CoreValve (CV) or Evolut R (EvR) implantation due to high/prohibitive risk for surgical redo. The MF size was 19 or 21 mm (off-label in Europe) in eight patients...
September 10, 2017: EuroIntervention
https://www.readbyqxmd.com/read/28888221/transcatheter-aortic-valve-in-valve-implantation-of-a-corevalve-in-a-jenavalve-prosthesis-a-case-report
#3
Shahram Lotfi, Michael Becker, Ajay Moza, Rüdiger Autschbach, Nikolaus Marx, Jörg Schröder
BACKGROUND: Transcatheter aortic valve implantation has become an accepted treatment modality for inoperable or high-risk surgical patients with symptomatic severe aortic stenosis. CASE PRESENTATION: We report the case of a 70-year-old white man who was treated for severe symptomatic aortic regurgitation using transcatheter aortic valve implantation from the apical approach. Because of recurrent cardiac decompensation 4 weeks after implantation he underwent the implantation of a left ventricular assist device system...
September 10, 2017: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/28818562/conduction-recovery-and-avoidance-of-permanent-pacing-after-transcatheter-aortic-valve-implantation
#4
Corinne Marzahn, Cornel Koban, Martin Seifert, Akihiro Isotani, Michael Neuß, Frank Hölschermann, Christian Butter
BACKGROUND: Transcatheter aortic valve implantation (TAVI) is an established treatment option for patients with severe aortic stenosis and high surgical risk. Currently, various prosthesis types are available. Atrioventricular block (AVB) requiring pacemaker (PM) implantation is a typical complication after TAVI. This study investigated the recovery of AV node conduction and mid-term outcome of patients with or without PM implantation after TAVI according to prosthesis type. METHODS: From July 2008 to May 2015, 856 transcatheter heart valves were implanted at our center (age: 80...
August 14, 2017: Journal of Cardiology
https://www.readbyqxmd.com/read/28797433/periprocedural-myocardial-injury-depends-on%C3%A2-transcatheter-heart-valve-type-but-does%C3%A2-not%C3%A2-predict-mortality-in-patients-after-transcatheter-aortic-valve-replacement
#5
Anja Stundl, Regina Schulte, Hannah Lucht, Marcel Weber, Alexander Sedaghat, Jasmin Shamekhi, Berndt Zur, Eberhard Grube, Fritz Mellert, Armin Welz, Rolf Fimmers, Georg Nickenig, Nikos Werner, Jan-Malte Sinning
OBJECTIVES: The aims of this study were to determine plasma elevations of biomarkers of myocardial injury associated with transfemoral (TF) transcatheter aortic valve replacement (TAVR) and to evaluate their prognostic value. BACKGROUND: Increases in biomarkers of myocardial injury are a common finding after TAVR, but their clinical significance is unclear. METHODS: In 756 consecutive TF TAVR patients, cardiac high-sensitivity troponin I (hsTnI) and creatine kinase MB (CK-MB) levels were measured at pre-defined time points to assess the occurrence of myocardial injury (defined as 15 times the upper reference limit for hsTnI [≥1...
August 14, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28797353/clinical-outcomes-with-a-repositionable-self-expanding-transcatheter-aortic%C3%A2-valve%C3%A2-prosthesis-the-international-forward-study
#6
MULTICENTER STUDY
Eberhard Grube, Nicolas M Van Mieghem, Sabine Bleiziffer, Thomas Modine, Johan Bosmans, Ganesh Manoharan, Axel Linke, Werner Scholtz, Didier Tchétché, Ariel Finkelstein, Ramiro Trillo, Claudia Fiorina, Antony Walton, Christopher J Malkin, Jae K Oh, Hongyan Qiao, Stephan Windecker
BACKGROUND: Clinical outcomes in large patient populations from real-world clinical practice with a next-generation self-expanding transcatheter aortic valve are lacking. OBJECTIVES: This study sought to document the clinical and device performance outcomes of transcatheter aortic valve replacement (TAVR) with a next-generation, self-expanding transcatheter heart valve (THV) system in patients with severe symptomatic aortic stenosis (AS) in routine clinical practice...
August 15, 2017: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/28760396/transcatheter-aortic-valve-replacement-with-new-generation-devices-a-systematic-review-and-meta-analysis
#7
Marco Barbanti, Sergio Buccheri, Josep Rodés-Cabau, Simona Gulino, Philippe Généreux, Gerlando Pilato, Danny Dvir, Andrea Picci, Giuliano Costa, Corrado Tamburino, Martin B Leon, John G Webb
OBJECTIVE: The aim of this study was to conduct a weighted meta-analysis to determine the rates of acute (≤30days) major outcomes after (TAVR) with second-generation devices. METHODS: A comprehensive search of multiple electronic databases from January 2011 to May 2017 was conducted using predefined criteria. New-generation TAVR devices were defined as any device which received CE mark approval or is still under evaluation for CE marking after CoreValve and SAPIEN XT prostheses...
July 25, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28724752/the-fluid-mechanics-of-transcatheter-heart-valve-leaflet-thrombosis-in-the-neo-sinus
#8
Prem A Midha, Vrishank Raghav, Rahul Sharma, Jose F Condado, Ikechukwu U Okafor, Tanya Rami, Gautam Kumar, Vinod H Thourani, Hasan Jilaihawi, Vasilis Babaliaros, Raj R Makkar, Ajit P Yoganathan
Background -Transcatheter heart valve (THV) thrombosis has been increasingly reported. In these studies, thrombus quantification has been based on 2D assessment of a 3D phenomenon. Methods -Post-procedural four-dimensional, volume-rendered CT (4DCT) data of CoreValve, Evolut R, and SAPIEN 3 transcatheter aortic valve replacement (TAVR) patients enrolled in the RESOLVE trial were included in this analysis. Patients on anticoagulation were excluded. SAPIEN 3 and CoreValve/Evolut R patients with and without hypo-attenuated leaflet thickening (HALT) were included in order to study differences between groups...
July 19, 2017: Circulation
https://www.readbyqxmd.com/read/28616543/transcatheter-aortic-valve-implantation-with-the-new-generation-evolut-r%C3%A2-comparison-with-corevalve%C3%A2-in-a-single-center-cohort
#9
Eberhard Schulz, Alexander Jabs, Tommaso Gori, Stephan von Bardeleben, Ulrich Hink, Walter Kasper-König, Christian Friedrich Vahl, Thomas Münzel
BACKGROUND: The Medtronic Evolut R (EVR) is a novel transcatheter heart valve designed to allow precise implantation at the intended position and to minimize prosthesis dysfunction as well as procedural complications. Our aim was to compare short-term functional and clinical outcomes of the new EVR with the established Medtronic CoreValve (CV) system. METHODS AND RESULTS: Of 151 patients undergoing transfemoral transcatheter aortic valve implantation with a self-expanding valve at our institution between January 2013 and January 2016, 86 were treated with EVR and 65 with CV...
September 2016: IJC Heart & Vasculature
https://www.readbyqxmd.com/read/28595747/transcathether-aortic-valve-implantation-with-the-new-repositionable-self-expandable-evolut-r-versus-corevalve-system-a-case-matched-comparison
#10
Cristina Giannini, Marco De Carlo, Corrado Tamburino, Federica Ettori, Azeem M Latib, Francesco Bedogni, Giuseppe Bruschi, Patrizia Presbitero, Arnaldo Poli, Franco Fabbiocchi, Roberto Violini, Carlo Trani, Pietro Giudice, Marco Barbanti, Marianna Adamo, Paola Colombo, Susanna Benincasa, Mauro Agnifili, A Sonia Petronio
BACKGROUND: Despite promising results following transcatheter aortic valve implantation (TAVI), several relevant challenges still remain. To overcome these issues, new generation devices have been developed. The purpose of the present study was to determine whether TAVI with the new self-expanding repositionable Evolut R offers potential benefits compared to the preceding CoreValve, using propensity matching. METHODS: Between June 2007 and November 2015, 2148 consecutive patients undergoing TAVI either CoreValve (n=1846) or Evolut R (n=302) were prospectively included in the Italian TAVI ClinicalService® project...
September 15, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28535198/transcatheter-aortic-valve-implantation-for-recurrent-valsalva-sinus-re-dissection-and-severe-aortic-regurgitation-shortly-after-surgery-for-type-a-aortic-dissection
#11
Elena Caporali, Giovanni Pedrazzini, Stefanos Demertzis, Enrico Ferrari
Delayed aortic regurgitation following Valsalva sinus re-dissection is a well-known complication that can occur at any time after surgery for type-A aortic dissection without root replacement. We describe a case of acute type-A dissection in an 81-year-old lady successfully treated with aortic valve resuspension and ascending aorta replacement with a 28-mm vascular graft. A month later, the patient was readmitted for worsening heart failure and a transthoracic echocardiogram showed severe aortic regurgitation secondary to non-coronary Valsalva sinus re-dissection and non-coronary aortic valve leaflet prolapse also confirmed at computed tomography scan...
May 23, 2017: Interactive Cardiovascular and Thoracic Surgery
https://www.readbyqxmd.com/read/28513189/transcatheter-aortic-valve-implantation-the-transaortic-approach
#12
Simon Cy Chow, Gary Sh Cheung, Alex Pw Lee, Eugene B Wu, Jacky Yk Ho, Micky Wt Kwok, Peter Sy Yu, Innes Yp Wan, Malcolm J Underwood, Randolph Hl Wong
Background Transcatheter aortic valve implantation has been established as a safe and effective treatment option for patients at high or prohibitive surgical risk. However, some patients may not be suitable for the transfemoral approach due to severe iliofemoral disease or aneurysmal disease of the thoracoabdominal aorta. The aim of this case series was to evaluate the feasibility and clinical outcomes of the transaortic approach. Methods From May 2015 to June 2016, 5 patients (mean age 78.4 ± 3.9 years) with severe symptomatic aortic stenosis underwent transaortic transcatheter aortic valve implantation after a heart team discussion...
June 2017: Asian Cardiovascular & Thoracic Annals
https://www.readbyqxmd.com/read/28493389/contemporary-transcatheter-aortic-valve-replacement-with-third-generation-balloon-expandable-versus-self-expanding-devices
#13
Toby Rogers, Arie Steinvil, Kyle Buchanan, M Chadi Alraies, Edward Koifman, Jiaxiang Gai, Rebecca Torguson, Petros Okubagzi, Itsik Ben-Dor, Augusto Pichard, Lowell Satler, Ron Waksman
OBJECTIVES: To evaluate balloon-expandable and self-expanding third-generation transcatheter aortic valve replacement (TAVR) devices according to patient selection criteria and outcomes. BACKGROUND: Two competing third-generation TAVR technologies are currently commercially available in the US. There are no published head-to-head comparisons of the relative performance of these two devices. METHODS: 257 consecutive patients undergoing TAVR with a third-generation balloon-expandable (Edwards Sapien 3) or self-expanding device (Medtronic CoreValve Evolut R) at a single US medical center were included...
May 11, 2017: Journal of Interventional Cardiology
https://www.readbyqxmd.com/read/28330793/outcomes-in-transcatheter-aortic-valve-replacement-for-bicuspid-versus-tricuspid%C3%A2-aortic%C3%A2-valve-stenosis
#14
MULTICENTER STUDY
Sung-Han Yoon, Sabine Bleiziffer, Ole De Backer, Victoria Delgado, Takahide Arai, Johannes Ziegelmueller, Marco Barbanti, Rahul Sharma, Gidon Y Perlman, Omar K Khalique, Erik W Holy, Smriti Saraf, Florian Deuschl, Buntaro Fujita, Philipp Ruile, Franz-Josef Neumann, Gregor Pache, Masao Takahashi, Hidehiro Kaneko, Tobias Schmidt, Yohei Ohno, Niklas Schofer, William K F Kong, Edgar Tay, Daisuke Sugiyama, Hiroyuki Kawamori, Yoshio Maeno, Yigal Abramowitz, Tarun Chakravarty, Mamoo Nakamura, Shingo Kuwata, Gerald Yong, Hsien-Li Kao, Michael Lee, Hyo-Soo Kim, Thomas Modine, S Chiu Wong, Francesco Bedgoni, Luca Testa, Emmanuel Teiger, Christian Butter, Stephan M Ensminger, Ulrich Schaefer, Danny Dvir, Philipp Blanke, Jonathon Leipsic, Fabian Nietlispach, Mohamed Abdel-Wahab, Bernard Chevalier, Corrado Tamburino, David Hildick-Smith, Brian K Whisenant, Seung-Jung Park, Antonio Colombo, Azeem Latib, Susheel K Kodali, Jeroen J Bax, Lars Søndergaard, John G Webb, Thierry Lefèvre, Martin B Leon, Raj Makkar
BACKGROUND: Transcatheter aortic valve replacement (TAVR) is being increasingly performed in patients with bicuspid aortic valve stenosis (AS). OBJECTIVES: This study sought to compare the procedural and clinical outcomes in patients with bicuspid versus tricuspid AS from the Bicuspid AS TAVR multicenter registry. METHODS: Outcomes of 561 patients with bicuspid AS and 4,546 patients with tricuspid AS were compared after propensity score matching, assembling 546 pairs of patients with similar baseline characteristics...
May 30, 2017: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/28283233/effect-of-transcatheter-aortic-valve-size-and-position-on-valve-in-valve-hemodynamics-an-in%C3%A2-vitro-study
#15
Ali N Azadani, Michael Reardon, Matheus Simonato, Gabriel Aldea, Georg Nickenig, Ran Kornowski, Danny Dvir
OBJECTIVE: Transcatheter heart valve implantation in failed aortic bioprostheses (valve-in-valve [ViV]) is an increasingly used therapeutic option for high-risk patients. However, high postprocedural gradients are a significant limitation of aortic ViV. Our objective was to evaluate Medtronic CoreValve Evolut R ViV hemodynamics in relation to the degree of device oversizing and depth of implantation. METHODS: Evolut R devices of 23 and 26 mm were implanted within 21-, 23-, and 25-mm Hancock II bioprostheses...
February 10, 2017: Journal of Thoracic and Cardiovascular Surgery
https://www.readbyqxmd.com/read/28183466/early-clinical-outcomes-after-transcatheter%C3%A2-aortic-valve-replacement-using-a-novel-self-expanding-bioprosthesis%C3%A2-in%C3%A2-patients-with-severe%C3%A2-aortic%C3%A2-stenosis-who-are-suboptimal%C3%A2-for%C3%A2-surgery-results-of-the-evolut-r-u-s-study
#16
Jeffrey J Popma, Michael J Reardon, Kamal Khabbaz, J Kevin Harrison, G Chad Hughes, Susheel Kodali, Isaac George, G Michael Deeb, Stan Chetcuti, Robert Kipperman, John Brown, Hongyan Qiao, James Slater, Mathew R Williams
OBJECTIVES: This study sought to evaluate this transcatheter aortic valve (TAV) bioprosthesis in patients who are poorly suitable for surgical aortic valve (AV) replacement. BACKGROUND: A novel self-expandable TAV bioprosthesis was designed to provide a low-profile delivery system, conformable annular sealing, and the ability to resheath and reposition during deployment. METHODS: The Evolut R U.S. study included 241 patients with severe aortic stenosis who were deemed to be at least high risk for surgery treated at 23 clinical sites in the United States...
February 13, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28145874/comparative-matched-outcome-of-evolut-r-vs-corevalve-transcatheter-aortic-valve-implantation
#17
Uri Landes, Tamir Bental, Alon Barsheshet, Abid Assali, Hana Vaknin Assa, Amos Levi, Katia Orvin, Ran Kornowski
OBJECTIVES: The Evolut-R (Medtronic, Inc) is a transcatheter aortic valve implantation (TAVI) system that was built on the well-established foundation of Medtronic's CoreValve device platform. Although already in extensive clinical utilization, it is unknown if the Evolut-R improves TAVI outcomes. Herein, we compared TAVI outcomes of the Evolut-R and CoreValve devices. METHODS: A propensity score 1:1 matching was conducted on 358 Evolut-R patients (n = 75) and CoreValve patients (n = 283)...
February 2017: Journal of Invasive Cardiology
https://www.readbyqxmd.com/read/28067197/comparison-of-procedural-and-clinical-outcomes-with-evolut-r-versus-medtronic-corevalve-a-swiss-tavi-registry-analysis
#18
Stephane Noble, Stefan Stortecky, Dik Heg, David Tuller, Raban Jeger, Stefan Toggweiler, Enrico Ferrari, Fabian Nietlispach, Maurizio Taramasso, Francesco Maisano, Jürg Grünenfelder, Peter Jüni, Christoph Huber, Thierry Carrel, Stephan Windecker, Peter Wenaweser, Marco Roffi
AIMS: Data on procedural and clinical outcomes after transcatheter aortic valve implantation (TAVI) with the new generation self-expanding Medtronic Evolut-R prosthesis in comparison with its predecessor, the Medtronic CoreValve, are scarce. METHODS AND RESULTS: In a nationwide, prospective, multi-center cohort study outcomes of consecutive transfemoral TAVI patients treated with the new- generation Medtronic Evolut-R (September 2014 - February 2016) and the Medtronic CoreValve (February 2011 - February 2016) were investigated...
January 10, 2017: EuroIntervention
https://www.readbyqxmd.com/read/28034684/thirty-day-outcome-following-corevalve-evolut-r-transcatheter-aortic-valve-implantation-an-all-comers-prospective-study
#19
Nils Perrin, Marco Roffi, Angela Frei, Anne-Lise Hachulla, Christoph Ellenberger, Hajo Müller, Mustafa Cikirikcioglu, Marc Licker, Stephane Noble
INTRODUCTION AND OBJECTIVES: There are scarce clinical outcomes data on the new generation recapturable and repositionable CoreValve Evolut R. METHODS: Data on all-comer patients undergoing transcatheter aortic valve implantation (TAVI) with the Evolut R for severe symptomatic aortic stenosis at a single center were prospectively collected between February 2015 and April 2016. Clinical endpoints were independently adjudicated according to the Valve Academic Research Consortium-2 criteria...
December 26, 2016: Revista Española de Cardiología
https://www.readbyqxmd.com/read/27970048/tct-672-outcomes-in-the-commercial-use-of-self-expanding-prostheses-in-transcatheter-aortic-valve-replacement-a-comparison-of-the-medtronic-corevalve-and-evolut-r-platforms-in-the-society-of-thoracic-surgeons-american-college-of-cardiology-transcatheter-valve
#20
Paul Sorajja, Susheel Kodali, Michael Reardon, Wilson Szeto, Stanley Chetcuti, James Hermiller, David Adams, Jeffrey Popma
No abstract text is available yet for this article.
November 1, 2016: Journal of the American College of Cardiology
keyword
keyword
49670
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"